Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11888312 | 0.90 | MAPK1 (0.67) | TSHRMAPK1HIF1AKDM4EADRB2 | |
| SCHEMBL22207426 | 0.86 | HIF1A (0.51) | ADRB3TSHRMAPK1CHRNB2CHRNA4 | |
| SCHEMBL22207352 | 0.84 | HIF1A (0.53) | ADRB3TSHRMAPK1CHRNB2CHRNA4 | |
| SCHEMBL2059732 | 0.83 | TSHR (0.68) | ADRB3TSHRMAPK1CHRNB2CHRNA4 | |
| SCHEMBL28618088 | 0.82 | ADRB3 (0.49) | ADRB3TSHRMAPK1CHRNB2CHRNA4 | |
| SCHEMBL7396426 | 0.81 | SMN1; SMN2 (0.53) | ADRB3TSHRMAPK1CHRNB2CHRNA4 | |
| SCHEMBL22207101 | 0.81 | PLA2G4B (0.47) | ADRB3TSHRMAPK1CHRNB2CHRNA4 | |
| SCHEMBL30306298 | 0.81 | PLA2G4B (0.47) | ADRB3TSHRMAPK1CHRNB2CHRNA4 | |
| SCHEMBL7510305 | 0.81 | LMNA (0.63) | ADRB3TSHRMAPK1CHRNB2CHRNA4 | |
| SCHEMBL15127448 | 0.81 | TSHR (0.56) | TSHRMAPK1HIF1AKDM4EADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378205-B2 | Process for the preparation of triazine intermediates and a process for the preparation of UV absorbers thereof | BASF SE (DE) | 2025-08-05 | — | — | US | disclosed |
| US-12291509-B2 | Process for the preparation of UV absorbers | BASF SE (DE) | 2025-05-06 | — | — | US | disclosed |
| EP-3908576-B1 | A PROCESS FOR THE PREPARATION OF UV ABSORBERS | BASF SE (DE) | 2023-03-08 | — | — | EP | disclosed |
| US-20220119357-A1 | A PROCESS FOR THE PREPARATION OF TRIAZINE INTERMEDIATES AND A PROCESS FOR THE PREPARATION OF UV ABSORBERS THEREOF | BASF SE (DE) | 2022-04-21 | — | — | US | disclosed |
| US-20220064129-A1 | A PROCESS FOR THE PREPARATION OF UV ABSORBERS | BASF CHEMICALS INDIA PVT. LTD. (IN) | 2022-03-03 | — | — | US | disclosed |
| EP-3908576-A1 | A PROCESS FOR THE PREPARATION OF UV ABSORBERS | BASF SE (DE) | 2021-11-17 | — | — | EP | disclosed |
| EP-3908633-A1 | A PROCESS FOR THE PREPARATION OF TRIAZINE INTERMEDIATES AND A PROCESS FOR THE PREPARATION OF UV ABSORBERS THEREOF | BASF SE (DE) | 2021-11-17 | — | — | EP | disclosed |
| CN-113260679-A | Process for preparing triazine intermediates and process for preparing UV absorbers thereof | 巴斯夫欧洲公司 | 2021-08-13 | — | — | CN | disclosed |
| CN-113260611-A | Method for producing UV absorbers | 巴斯夫欧洲公司 | 2021-08-13 | — | — | CN | disclosed |
| WO-2020144094-A1 | A PROCESS FOR THE PREPARATION OF UV ABSORBERS | BASF SE (DE) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020144093-A1 | A PROCESS FOR THE PREPARATION OF TRIAZINE INTERMEDIATES AND A PROCESS FOR THE PREPARATION OF UV ABSORBERS THEREOF | BASF SE (DE) | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119357-A1 | A PROCESS FOR THE PREPARATION OF TRIAZINE INTERMEDIATES AND A PROCESS FOR THE PREPARATION OF UV ABSORBERS THEREOF | DHPS, NISCH, UNG | ADRB3 4390/4885TSHR 1439/4885MAPK1 4609/4885 |
| US-12378205-B2 | Process for the preparation of triazine intermediates and a process for the preparation of UV absorbers thereof | DHPS, UNG, UMPS | ADRB3 4303/4885TSHR 1518/4885MAPK1 4609/4885 |
| US-20220064129-A1 | A PROCESS FOR THE PREPARATION OF UV ABSORBERS | UNG, ERCC4, UROD | ADRB3 4493/4885TSHR 3632/4885MAPK1 4863/4885 |
| US-12291509-B2 | Process for the preparation of UV absorbers | UNG, UROD, ERCC4 | ADRB3 4399/4885TSHR 3523/4885MAPK1 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.